{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:50:45Z","timestamp":1791435045158,"version":"4.3.3"},"reference-count":98,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Else Kr\u00f6ner-Fresenius Foundation"},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["SFB1192"],"award-info":[{"award-number":["SFB1192"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["KR-3483\/3-1"],"award-info":[{"award-number":["KR-3483\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Immune-mediated kidney diseases have a substantial disease burden and frequent disease relapses significantly contribute to the high morbidity. Relapsing disease courses are associated with poor outcome and accelerated progression to end-stage renal disease. The pathomechanisms leading to relapse are diverse and only incompletely understood. Both adaptive and innate immune cells are implicated in the immune memory of these diseases. In addition to antigen-dependent mechanisms of T and B cells, persistent epigenetic and metabolic changes in adaptive and innate immune cells may sustain immunological memory and thereby provide a cellular and molecular basis for relapse. Treatment options, especially in frequently relapsing cases, are limited and memory immune cells often evade standard immunosuppressive therapies. As our understanding of immunological memory continues to improve, new treatment options emerge. Improved depletion of B cells, antigen-specific cell-based therapies and redirecting epigenetic alterations may target long-lasting immune memory. This could reduce relapse risk and improve long-term outcomes in patients with immune-mediated kidney diseases.<\/jats:p>","DOI":"10.1093\/ckj\/sfag299","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:11:31Z","timestamp":1788520291000},"source":"Crossref","is-referenced-by-count":0,"title":["Targeting tissue immune memory in chronic-remitting autoimmune kidney diseases: current concepts and future therapies"],"prefix":"10.1093","volume":"19","author":[{"given":"Malte","family":"Hellmig","sequence":"first","affiliation":[{"name":"III. Department of Medicine, University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]},{"name":"Hamburg Center for Translational Immunology (HCTI), University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]},{"name":"Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2739-5578","authenticated-orcid":false,"given":"Christian F","family":"Krebs","sequence":"additional","affiliation":[{"name":"III. Department of Medicine, University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]},{"name":"Hamburg Center for Translational Immunology (HCTI), University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]},{"name":"Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"2026100800165684300_bib1","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"Mark","year":"2025","journal-title":"Lancet"},{"key":"2026100800165684300_bib2","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(23)02843-X","article-title":"Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort","volume":"403","author":"Wong","year":"2024","journal-title":"Lancet"},{"key":"2026100800165684300_bib3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/rheumatology\/key260","article-title":"Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome","volume":"58","author":"Wester\u00a0Trejo","year":"2019","journal-title":"Rheumatology"},{"key":"2026100800165684300_bib4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2215\/CJN.05040513","article-title":"Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis","volume":"9","author":"Parikh","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026100800165684300_bib5","doi-asserted-by":"publisher","first-page":"aaf1098","DOI":"10.1126\/science.aaf1098","article-title":"Trained immunity: a program of innate immune memory in health and disease","volume":"352","author":"Netea","year":"2016","journal-title":"Science"},{"key":"2026100800165684300_bib6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1128\/iai.51.2.668-674.1986","article-title":"Evidence for macrophage-mediated protection against lethal Candida albicans infection","volume":"51","author":"Bistoni","year":"1986","journal-title":"Infect Immun"},{"key":"2026100800165684300_bib7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nature07665","article-title":"Adaptive immune features of natural killer cells","volume":"457","author":"Sun","year":"2009","journal-title":"Nature"},{"key":"2026100800165684300_bib8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.chom.2017.12.010","article-title":"BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity","volume":"23","author":"Arts","year":"2018","journal-title":"Cell Host Microbe"},{"key":"2026100800165684300_bib9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.chom.2012.06.006","article-title":"Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes","volume":"12","author":"Quintin","year":"2012","journal-title":"Cell Host Microbe"},{"key":"2026100800165684300_bib10","doi-asserted-by":"publisher","first-page":"1251086","DOI":"10.1126\/science.1251086","article-title":"Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity","volume":"345","author":"Saeed","year":"2014","journal-title":"Science"},{"key":"2026100800165684300_bib11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41588-018-0298-2","article-title":"Immune genes are primed for robust transcription by proximal long noncoding RNAs located in nuclear compartments","volume":"51","author":"Fanucchi","year":"2019","journal-title":"Nat Genet"},{"key":"2026100800165684300_bib12","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/art.38964","article-title":"Interferon regulatory factor 1 marks activated genes and can induce target gene expression in systemic lupus erythematosus","volume":"67","author":"Zhang","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2026100800165684300_bib13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","article-title":"ANCA-associated vasculitis","volume":"6","author":"Kitching","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026100800165684300_bib14","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2026100800165684300_bib15","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1001\/jama.2025.25020","article-title":"IgA nephropathy in adults: a review","volume":"335","author":"Stoneman","year":"2026","journal-title":"JAMA"},{"key":"2026100800165684300_bib16","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1093\/ndt\/gfm781","article-title":"External suppression causes the low expression of the Cosmc gene in IgA nephropathy","volume":"23","author":"Qin","year":"2008","journal-title":"Nephrol Dial Transpl"},{"key":"2026100800165684300_bib17","doi-asserted-by":"publisher","first-page":"e0112305","DOI":"10.1371\/journal.pone.0112305","article-title":"DNA methylation in Cosmc promoter region and aberrantly glycosylated IgA1 associated with pediatric IgA nephropathy","volume":"10","author":"Sun","year":"2015","journal-title":"PLoS One"},{"key":"2026100800165684300_bib18","doi-asserted-by":"publisher","first-page":"274ra18","DOI":"10.1126\/scitranslmed.aaa0835","article-title":"Normalization of CD4+ T cell metabolism reverses lupus","volume":"7","author":"Yin","year":"2015","journal-title":"Sci Transl Med"},{"key":"2026100800165684300_bib19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1021\/acsptsci.3c00219","article-title":"RVX-208): a potential epigenetic therapy for the treatment of cardiovascular, renal, neurological, viral, and cancer disorders","volume":"7","author":"Dhulkifle","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2026100800165684300_bib20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2215\/CJN.16751020","article-title":"Effect of apabetalone on cardiovascular events in diabetes, CKD, and recent acute coronary syndrome: results from the BETonMACE randomized controlled trial","volume":"16","author":"Kalantar-Zadeh","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026100800165684300_bib21","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1093\/ndt\/gfy009","article-title":"Targeting epigenetic DNA and histone modifications to treat kidney disease","volume":"33","author":"Fontecha-Barriuso","year":"2018","journal-title":"Nephrol Dial Transpl"},{"key":"2026100800165684300_bib22","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/j.ajt.2024.08.006","article-title":"Trained immunity suppression determines kidney allograft survival","volume":"24","author":"Jonkman","year":"2024","journal-title":"Am J Transpl"},{"key":"2026100800165684300_bib23","doi-asserted-by":"publisher","first-page":"e70152","DOI":"10.1371\/journal.pone.0070152","article-title":"A shift towards pro-inflammatory CD16+ monocyte subsets with preserved cytokine production potential after kidney transplantation","volume":"8","author":"Vereyken","year":"2013","journal-title":"PLoS One"},{"key":"2026100800165684300_bib24","doi-asserted-by":"publisher","first-page":"e0199445","DOI":"10.1371\/journal.pone.0199445","article-title":"Delayed graft function is associated with an increased rate of renal allograft rejection: a retrospective single center analysis","volume":"13","author":"Weber","year":"2018","journal-title":"PLoS One"},{"key":"2026100800165684300_bib25","doi-asserted-by":"publisher","first-page":"7385","DOI":"10.1038\/s41467-023-43315-x","article-title":"Fatty acid desaturation and lipoxygenase pathways support trained immunity","volume":"14","author":"Ferreira","year":"2023","journal-title":"Nat Commun"},{"key":"2026100800165684300_bib26","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1681\/ASN.2017010030","article-title":"A heterologous model of thrombospondin type 1 domain-containing 7a-associated membranous nephropathy","volume":"28","author":"Tomas","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026100800165684300_bib27","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.kint.2023.07.024","article-title":"Introduction of a novel chimeric active immunization mouse model of PLA2R1-associated membranous nephropathy","volume":"104","author":"Tomas","year":"2023","journal-title":"Kidney Int"},{"key":"2026100800165684300_bib28","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40620-022-01508-5","article-title":"Relationship between anti-GBM antibodies and kidney outcomes in patients with anti-GBM disease","volume":"36","author":"Zhu","year":"2023","journal-title":"J Nephrol"},{"key":"2026100800165684300_bib29","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.kint.2025.08.026","article-title":"Patient anti-PLA2R1 autoantibodies cause membranous nephropathy in human PLA2R1 transgenic mice","volume":"108","author":"Zahner","year":"2025","journal-title":"Kidney Int"},{"key":"2026100800165684300_bib30","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1093\/ndt\/gfn761","article-title":"Levels of epitope-specific autoantibodies correlate with renal damage in anti-GBM disease","volume":"24","author":"Yang","year":"2009","journal-title":"Nephrol Dial Transpl"},{"key":"2026100800165684300_bib31","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2026100800165684300_bib32","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","article-title":"2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)\u2013Associated Vasculitis","volume":"105","author":"Floege","year":"2024","journal-title":"Kidney Int"},{"key":"2026100800165684300_bib33","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1073\/pnas.87.11.4115","article-title":"Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro","volume":"87","author":"Falk","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026100800165684300_bib34","doi-asserted-by":"crossref","first-page":"e0165402","DOI":"10.1371\/journal.pone.0165402","article-title":"ANCA-associated glomerulonephritis: risk factors for renal relapse","volume":"11","author":"G\u00f6\u00e7ero\u011flu","year":"2016","journal-title":"PLoS One"},{"key":"2026100800165684300_bib35","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1681\/ASN.2013111233","article-title":"ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease","volume":"26","author":"Kemna","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2026100800165684300_bib36","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/ard-2022-223559","article-title":"Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial","volume":"82","author":"Smith","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026100800165684300_bib37","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/blood-2014-02-555169","article-title":"A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow","volume":"125","author":"Mei","year":"2015","journal-title":"Blood"},{"key":"2026100800165684300_bib38","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ki.2008.191","article-title":"Analysis and classification of B-cell infiltrates in lupus and ANCA-associated nephritis","volume":"74","author":"Steinmetz","year":"2008","journal-title":"Kidney Int"},{"key":"2026100800165684300_bib39","doi-asserted-by":"publisher","first-page":"e002742","DOI":"10.1136\/rmdopen-2022-002742","article-title":"Daratumumab for the treatment of refractory ANCA-associated vasculitis","volume":"9","author":"Ostendorf","year":"2023","journal-title":"RMD Open"},{"key":"2026100800165684300_bib40","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"2026100800165684300_bib41","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.kint.2025.05.028","article-title":"Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy","volume":"108","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"2026100800165684300_bib42","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.ard.2025.01.008","article-title":"Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis","volume":"84","author":"Minopoulou","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2026100800165684300_bib43","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.ekir.2024.01.016","article-title":"Effect of sustained clinical remission on the risk of lupus flares and impaired kidney function in patients with lupus nephritis","volume":"9","author":"Gatto","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026100800165684300_bib44","doi-asserted-by":"publisher","first-page":"e000533","DOI":"10.1136\/lupus-2021-000533","article-title":"Absence of renal remission portends poor long-term kidney outcome in lupus nephritis","volume":"8","author":"Pirson","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026100800165684300_bib45","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2026100800165684300_bib46","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100800165684300_bib47","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell\u2013mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"2026100800165684300_bib48","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/art.27189","article-title":"Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study","volume":"62","author":"Jacobi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2026100800165684300_bib49","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/ndt\/16.3.513","article-title":"Increased intestinal intra-epithelial T lymphocytes in primary glomerulonephritis","volume":"16","author":"Rostoker","year":"2001","journal-title":"Nephrol Dial Transpl"},{"key":"2026100800165684300_bib50","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.kint.2025.12.026","article-title":"Multi-omics analyses reveal the pathogenic role of terminal ileum-derived IgA+\u03b27+ cells in IgA nephropathy","volume":"109","author":"Liu","year":"2026","journal-title":"Kidney Int"},{"key":"2026100800165684300_bib51","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"2026100800165684300_bib52","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1056\/NEJMoa2510198","article-title":"A phase 3 trial of atacicept in patients with IgA nephropathy","volume":"394","author":"Lafayette","year":"2026","journal-title":"N Engl J Med"},{"key":"2026100800165684300_bib53","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2512133","article-title":"Sibeprenlimab in IgA nephropathy\u2014interim analysis of a phase 3 trial","volume":"394","author":"Perkovic","year":"2026","journal-title":"N Engl J Med"},{"key":"2026100800165684300_bib54","doi-asserted-by":"publisher","first-page":"e0196101","DOI":"10.1371\/journal.pone.0196101","article-title":"Early post-transplant serum IgA level is associated with IgA nephropathy recurrence after kidney transplantation","volume":"13","author":"Garnier","year":"2018","journal-title":"PLoS One"},{"key":"2026100800165684300_bib55","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3389\/fimmu.2020.02068","article-title":"Association between galactose-deficient IgA1 derived from the tonsils and recurrence of IgA nephropathy in patients who underwent kidney transplantation","volume":"11","author":"Kawabe","year":"2020","journal-title":"Front Immunol"},{"key":"2026100800165684300_bib56","doi-asserted-by":"publisher","first-page":"e14320","DOI":"10.1111\/ctr.14320","article-title":"Incidence, risk factors, treatment, and consequences of antibody-mediated kidney transplant rejection: a systematic review","volume":"35","author":"Hart","year":"2021","journal-title":"Clin Transpl"},{"key":"2026100800165684300_bib57","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1111\/ajt.16463","article-title":"Long-term kidney transplant graft survival\u2014making progress when most needed","volume":"21","author":"Poggio","year":"2021","journal-title":"Am J Transpl"},{"key":"2026100800165684300_bib58","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients","volume":"9","author":"Eckardt","year":"2009","journal-title":"Am J Transpl"},{"key":"2026100800165684300_bib59","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1681\/ASN.2017070818","article-title":"A Randomized trial of bortezomib in late antibody-mediated kidney transplant rejection","volume":"29","author":"Eskandary","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2026100800165684300_bib60","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.1016\/j.ekir.2025.07.009","article-title":"Anti-CD38 Daratumumab treatment of chronic active antibody-mediated kidney allograft rejection","volume":"10","author":"Lye","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026100800165684300_bib61","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa2400763","article-title":"A randomized phase 2 trial of felzartamab in antibody-mediated rejection","volume":"391","author":"Mayer","year":"2024","journal-title":"N Engl J Med"},{"key":"2026100800165684300_bib62","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/tan.15156","article-title":"Chimeric HLA antibody receptor T cells for targeted therapy of antibody-mediated rejection in transplantation","volume":"102","author":"Betriu","year":"2023","journal-title":"HLA"},{"key":"2026100800165684300_bib63","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"2026100800165684300_bib64","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.kint.2025.09.028","article-title":"Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells","volume":"109","author":"Altun","year":"2026","journal-title":"Kidney Int"},{"key":"2026100800165684300_bib65","doi-asserted-by":"publisher","first-page":"1111521","DOI":"10.3389\/fimmu.2023.1111521","article-title":"Tissue-resident memory T cells in renal autoimmune diseases","volume":"14","author":"Ginsberg","year":"2023","journal-title":"Front Immunol"},{"key":"2026100800165684300_bib66","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41577-025-01131-y","article-title":"Kidney immunology from pathophysiology to clinical translation","volume":"25","author":"Kurts","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"2026100800165684300_bib67","doi-asserted-by":"publisher","first-page":"eaba4163","DOI":"10.1126\/sciimmunol.aba4163","article-title":"Pathogen-induced tissue-resident memory TH 17 (TRM 17) cells amplify autoimmune kidney disease","volume":"5","author":"Krebs","year":"2020","journal-title":"Sci Immunol"},{"key":"2026100800165684300_bib68","doi-asserted-by":"publisher","first-page":"102424","DOI":"10.1016\/j.jaut.2020.102424","article-title":"JAK\/STAT signaling controls the fate of CD8+CD103+ tissue-resident memory T cell in lupus nephritis","volume":"109","author":"Zhou","year":"2020","journal-title":"J Autoimmun"},{"key":"2026100800165684300_bib69","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature21379","article-title":"Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism","volume":"543","author":"Pan","year":"2017","journal-title":"Nature"},{"key":"2026100800165684300_bib70","doi-asserted-by":"publisher","first-page":"20207","DOI":"10.1021\/acs.jmedchem.5c01256","article-title":"Discovery of potent and selective FABP4\/5 inhibitors with an isoquinolone scaffold as potential therapeutics for inflammation-related diseases","volume":"68","author":"He","year":"2025","journal-title":"J Med Chem"},{"key":"2026100800165684300_bib71","doi-asserted-by":"publisher","first-page":"eadd8454","DOI":"10.1126\/sciimmunol.add8454","article-title":"Tissue-resident memory T cell maintenance during antigen persistence requires both cognate antigen and interleukin-15","volume":"8","author":"Tieu","year":"2023","journal-title":"Sci Immunol"},{"key":"2026100800165684300_bib72","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.4049\/jimmunol.1002188","article-title":"Contribution of astrocyte-derived IL-15 to CD8 T cell effector functions in multiple sclerosis","volume":"185","author":"Saikali","year":"2010","journal-title":"J Immunol"},{"key":"2026100800165684300_bib73","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/gut.2005.068684","article-title":"Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease","volume":"55","author":"Di\u00a0Sabatino","year":"2006","journal-title":"Gut"},{"key":"2026100800165684300_bib74","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nm0297-189","article-title":"Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-\u03b1 production in rheumatoid arthritis","volume":"3","author":"McInnes","year":"1997","journal-title":"Nat Med"},{"key":"2026100800165684300_bib75","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12979-022-00305-9","article-title":"Excessive IL-15 promotes cytotoxic CD4 + CD28\u2212 T cell-mediated renal injury in lupus nephritis","volume":"19","author":"Zhang","year":"2022","journal-title":"Immun Ageing"},{"key":"2026100800165684300_bib76","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.ekir.2024.01.010","article-title":"Protective Role of the podocyte IL-15 \/STAT5 pathway in focal segmental glomerulosclerosis","volume":"9","author":"Niasse","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026100800165684300_bib77","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/ni.2745","article-title":"Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells","volume":"14","author":"Skon","year":"2013","journal-title":"Nat Immunol"},{"key":"2026100800165684300_bib78","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/intimm\/dxn044","article-title":"Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE)","volume":"20","author":"Bonelli","year":"2008","journal-title":"Int Immunol"},{"key":"2026100800165684300_bib79","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.molimm.2019.11.010","article-title":"Reduced activated regulatory T cells and imbalance of Th17\/activated Treg cells marks renal involvement in ANCA-associated vasculitis","volume":"118","author":"Wang","year":"2020","journal-title":"Mol Immunol"},{"key":"2026100800165684300_bib80","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/biomedicines10020287","article-title":"CAR-T regulatory (CAR-Treg) cells: engineering and applications","volume":"10","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicines"},{"key":"2026100800165684300_bib81","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","article-title":"Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus","volume":"15","author":"Doglio","year":"2024","journal-title":"Nat Commun"},{"key":"2026100800165684300_bib82","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.kint.2026.06.042","article-title":"Early acute T cell-mediated rejection and kidney allograft outcomes","volume":"110","author":"Chen","year":"2026","journal-title":"Kidney Int"},{"key":"2026100800165684300_bib83","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00467-011-1798-9","article-title":"Antithymocyte treatment of steroid-resistant acute rejection in renal transplantation","volume":"26","author":"Shenoy","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"2026100800165684300_bib84","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1681\/ASN.2019080847","article-title":"Terminally differentiated effector memory CD8+ T cells identify kidney transplant recipients at high risk of graft failure","volume":"31","author":"Jacquemont","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026100800165684300_bib85","doi-asserted-by":"publisher","first-page":"eabc8122","DOI":"10.1126\/sciimmunol.abc8122","article-title":"Resident memory T cells form during persistent antigen exposure leading to allograft rejection","volume":"6","author":"Abou-Daya","year":"2021","journal-title":"Sci Immunol"},{"key":"2026100800165684300_bib86","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/TP.0000000000003136","article-title":"KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation","volume":"104","author":"Chadban","year":"2020","journal-title":"Transplantation"},{"key":"2026100800165684300_bib87","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 glomerulopathy: clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026100800165684300_bib88","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1681\/ASN.2013070715","article-title":"Clinical findings, pathology, and outcomes of C3GN after kidney transplantation","volume":"25","author":"Zand","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2026100800165684300_bib89","doi-asserted-by":"publisher","first-page":"101104","DOI":"10.1016\/j.xkme.2025.101104","article-title":"Association Between relapse and long-term kidney outcomes in IgA nephropathy","volume":"7","author":"Shen","year":"2025","journal-title":"Kidney Med"},{"key":"2026100800165684300_bib90","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1111\/j.1600-6143.2006.01502.x","article-title":"Recurrent glomerulonephritis after kidney transplantation","volume":"6","author":"Choy","year":"2006","journal-title":"Am J Transpl"},{"key":"2026100800165684300_bib91","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jaad.2026.02.007","article-title":"Updates on the diagnosis, prognosis, and management of IgA vasculitis in adults: a narrative review","volume":"95","author":"Stichert","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"2026100800165684300_bib92","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.2215\/CJN.00520111","article-title":"Recurrence and graft loss after kidney transplantation for Henoch\u2013Sch\u00f6nlein purpura nephritis: a multicenter analysis","volume":"6","author":"Kanaan","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026100800165684300_bib93","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1046\/j.1523-1755.1999.00666.x","article-title":"Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis","volume":"56","author":"Nachman","year":"1999","journal-title":"Kidney Int"},{"key":"2026100800165684300_bib94","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1111\/j.1600-6143.2007.01904.x","article-title":"The long-term prognosis of renal transplant in patients with systemic vasculitis","volume":"7","author":"Moroni","year":"2007","journal-title":"Am J Transpl"},{"key":"2026100800165684300_bib95","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1681\/ASN.2009101093","article-title":"Recurrence of lupus nephritis after kidney transplantation","volume":"21","author":"Contreras","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2026100800165684300_bib96","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1136\/ard.2009.122796","article-title":"Recurrent lupus nephritis after kidney transplantation: a surveillance biopsy study","volume":"69","author":"Norby","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026100800165684300_bib97","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/j.1523-1755.2004.00873.x","article-title":"Idiopathic membranous nephropathy: definition and relevance of a partial remission","volume":"66","author":"Troyanov","year":"2004","journal-title":"Kidney Int"},{"key":"2026100800165684300_bib98","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1097\/TP.0000000000001056","article-title":"Recurrent membranous nephropathy after kidney transplantation: treatment and long-term implications","volume":"100","author":"Grupper","year":"2016","journal-title":"Transplantation"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag299\/70984121\/sfag299.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/10\/sfag299\/70984121\/sfag299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/10\/sfag299\/70984121\/sfag299.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:17:05Z","timestamp":1791433025000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag299\/8787371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":98,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag299","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,7]]},"article-number":"sfag299"}}